Visa's $8 dispute fee pressures Hims & Hers subscription model

Visa placed Hims & Hers Health into its Acquirer Monitoring Program after a surge in billing disputes, levying an $8 fee per contested transaction that could reach $75,000 monthly for the telehealth platform.

"We take our responsibility to be transparent with our almost 3 million subscribers seriously," a Hims & Hers spokesperson said, noting the company is working on clearer alerts about upcoming charges.

The penalty follows a late-July lawsuit from the Federal Trade Commission and the attorneys general of California and Utah alleging deceptive billing practices. The complaint claims Hims & Hers trapped users in recurring subscriptions by obscuring cancellation processes. To exit the program, Hims must keep disputes below 1.5 percent of transactions for three consecutive months.

HIMS shares fell 9.45 percent to $30.59 on the news, while the stock's 52-week range spans $13.74 to $65.30. The company's gross margin already contracted to roughly 64 percent from 76 percent year over year in the second quarter, and adjusted EBITDA guidance for the third quarter came in below analyst expectations.

Tollbooth Economics: Visa Collects While Hims Pays

The $8 per-dispute surcharge functions as a systemic tax on Hims & Hers' revenue engine. The aggregate penalty, approaching roughly $75,000 for a single recent month, is less concerning than what it represents: a structural flaw in customer retention that regulators and payment networks are no longer willing to ignore.

Visa's asset-light model allows it to maintain net margins near 51 percent. The payment network collects standard processing fees plus newly imposed penalty surcharges, entirely insulated from the regulatory turbulence shaking the telehealth space. Visa does not assume customer acquisition risk, yet it participates in every transaction.

For Hims & Hers, the math is more punishing. The company's subscription model charges $39 for the first month, then $149 monthly with automatic renewal. Customers who struggle to cancel bypass customer service and initiate chargebacks with their card providers. Each dispute now carries an $8 penalty, and the company must suppress its dispute rate below 1.5 percent for three consecutive months to exit the program.

The compliance measures required to fix this — clearer cancellation buttons, mandatory opt-in confirmations, billing transparency overhauls — inherently slow down the high-speed customer acquisition funnel. Any deceleration in subscriber additions forces the market to reprice the valuation multiple.

Insider activity adds another layer of concern. The 12-month insider trading profile for Hims & Hers shows nearly $60 million in annualized selling against negligible open-market purchases. Payment processor Stripe reportedly notified Hims & Hers of its penalized status in early August, and shortly after, the Chief Financial Officer liquidated over 14,000 shares through block sales.

The Peptide Pipeline Offers a Bullish Bypass

A purely bearish outlook ignores the structural tailwinds that could overpower these payment-processing friction costs. Hims & Hers has experienced a strong revenue surge driven by its aggressive rollout of compounded GLP-1 weight-loss peptides. This segment operates in a complex regulatory environment dependent on federal drug shortage classifications.

The Food and Drug Administration allows compounding pharmacies to recreate branded medications when the original drugs are in national shortage. Should the regulatory conditions shift favorably, or if Hims & Hers successfully scales its customized peptide offerings without federal interference, the resulting top-line expansion could dwarf the Visa penalties.

The stock trades at a price-to-sales ratio just over 3, indicating the market is still pricing in sustained, aggressive growth. Hims is also shifting toward partnerships with established drugmakers like Novo Nordisk, moving away from compounded versions of popular weight-loss drugs.

For investors, the choice is between the infrastructure layer and the growth layer. Holding a payment network like Visa allows exposure to transaction volume across the entire consumer health sector, collecting consistent tolls regardless of which telehealth platform wins the market share battle. Hims & Hers offers explosive upside optionality through its peptide pipeline, but carries the regulatory and compliance risk of the current penalty program. The upcoming earnings cycle will determine whether the company can lower its dispute rate without throttling new customer additions.

This article is for informational purposes only and does not constitute investment advice.